SGLT2 inhibitors


SGLT2 inhibitors (also Gliflozin or Flozin called) are a modern class of active ingredients for the treatment of type 2 diabetes. They act independently of insulin by inhibiting the reabsorption of glucose in the kidneys - the excess sugar is simply excreted in the urine.

Mode of action

SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidneys. This will:

  • Approximately 60–100 g of glucose is excreted in the urine every day
  • Blood sugar levels lowered
  • A calorie loss of around 240-400 kcal per day is achieved
  • Blood pressure slightly lowered (through natriuresis)

Important active ingredients and preparations (as of 2026)

active ingredient Brand names Typical dosage
Empagliflozin Jardiance 10-25 mg once daily
Dapagliflozin Forxiga 5-10 mg once daily
Canagliflozin Invokana 100-300 mg once daily
Ertugliflozin Steglatro 5-15 mg once daily

Advantages

  • Weight loss (2–4 kg)
  • Lowering blood pressure
  • Strong protection for the heart and kidneys (less heart failure, less kidney failure)
  • No increased risk of hypoglycemia with monotherapy

Side effects and safety

Common: genital fungal infections and urinary tract infections. Important: Take a temporary break in the event of illness, vomiting or surgery (sick day rule) to avoid the risk of ketoacidosis.

Further information:
Diabetes mellitus – knowledge and overview
Why hyporest
Type 2 diabetes

Sources

  1. German Diabetes Society (DDG). S3 guideline “Type 2 diabetes”. As of 2025. Available at: www.deutsche-diabetes-gesellschaft.de/leitlinien.
  2. American Diabetes Association. Standards of Medical Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). Available at: diabetesjournals.org.
  3. Robert Koch Institute (RKI). Federal health reporting – diabetes mellitus in Germany. Berlin 2024.
  4. International Diabetes Federation (IDF). IDF Diabetes Atlas. 11th edition. Brussels 2025. Available at: diabetesatlas.org.

Important note:
The information in this encyclopedia article is intended solely for general and non-binding information. They do not replace medical advice, diagnosis or therapy. If you have any health questions or complaints, please always consult a doctor or qualified healthcare professional. The content was created with the greatest possible care, but errors cannot be completely ruled out.

Last updated: February 26, 2026


Unser Blog wird fachlich gegengelesen von Daniela MikaDiabetesberaterin (DDG)

Daniela Mika begleitet seit über 20 Jahren Menschen mit Diabetes, mit Schwerpunkt auf der Insulinpumpentherapie. Neben ihrer Arbeit am Krankenhaus in Lippstadt ist sie Referentin auf Fachveranstaltungen und setzt sich aktiv für Frauengesundheit bei Diabetes ein.